文献速递胸部肿瘤放疗

每日赖诺普利与安慰剂预防肺癌患者放化疗所致肺部不适(Alliance MC1221):一项先导性双盲随机试验

Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-11-02

该先导性双盲安慰剂对照随机试验在5家机构纳入23例接受根治性胸部放疗并同步化疗的肺癌患者,随机接受每日20 mg赖诺普利或安慰剂至放疗后3个月,主要终点为不良事件分析。结果显示两组均未发生3级及以上低血压、急性肾损伤、药物性咳嗽或血管性水肿;少数患者报告结局指标提示赖诺普利组咳嗽、气短、肺癌症状、行走及爬楼时呼吸困难较少且总体生活质量更好(均P<.05),但因入组不足把握度低,作者认为需开展更大规模3期随机试验。

要点

  • 5家机构共入组23例,赖诺普利组12例、安慰剂组11例,入组低于预期。
  • 两组均未发生3级及以上低血压、急性肾损伤、药物性咳嗽或血管性水肿。
  • 少数患者报告结局指标提示赖诺普利组咳嗽、气短、呼吸困难较少且生活质量更好(均P<.05)。

核心结论

  • 因入组低而把握度不足,结果提示胸部放化疗期间同步使用赖诺普利存在安全性信号,并可能通过有限的患者报告结局指标显示获益,有助于减轻或预防放疗所致肺部不适。
  • 作者认为未来需要开展确证性、更大规模的3期随机试验。

研究设计与样本

  • 先导性、双盲、安慰剂对照随机试验,在5家机构纳入23例接受根治性胸部放疗并同步化疗的肺癌患者。
  • 患者随机接受每日20 mg赖诺普利或安慰剂,用药持续至放疗结束后3个月。
  • 主要终点为不良事件分析,采用肺癌症状量表、癌症治疗功能评估-肺、欧洲癌症研究与治疗组织肺癌问卷及症状体验问卷进行患者报告结局调查,探索性比较采用χ2检验与Kruskal-Wallis检验。

主要发现

  • 赖诺普利组12例、安慰剂组11例,平均年龄63.5岁,男性占62%,基线特征均衡,18例(86%)为既往或当前吸烟者。
  • 主要终点达标:两组均未发生3级及以上低血压、急性肾损伤、过敏性反应(药物性咳嗽)或过敏反应(药物相关血管性水肿)。
  • 少数患者报告结局指标提示,与安慰剂组相比,赖诺普利组咳嗽较少、气短较少、肺癌症状较少、行走及爬楼时呼吸困难较少且总体生活质量更好(均P<.05)。

临床怎么用

  • 作者认为,胸部放化疗期间同步使用赖诺普利存在安全性信号,并可能通过有限的患者报告结局指标显示获益,但该结果因入组低而把握度不足。
  • 作者认为未来需要开展确证性、更大规模的3期随机试验。

局限性

  • 入组低于预期,研究把握度不足。
  • 作者指出未来需要开展确证性、更大规模的3期随机试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Chemoradiation (CRT) is an integral treatment modality for patients with locally advanced lung cancer. It has been hypothesized that current use of an angiotensin-converting enzyme inhibitor during CRT may be protective for treatment-related lung damage and pneumonitis. METHODS AND MATERIALS: We conducted a pilot, double-blind, placebo-controlled, randomized trial. Study-eligible patients receiving curative thoracic radiation therapy (RT) were randomly assigned to 20 mg of lisinopril or placebo once daily during and up to 3 months after RT. All patients received concurrent chemotherapy. The primary endpoint was adverse event profiling. Multiple patient-reported outcome (PRO) surveys, including the Lung Cancer Symptom Scale, Function Assessment of Cancer Therapy-Lung, and the European Organisation for Research and Treatment of Cancer Lung Cancer Questionnaire, were applied with a symptom experience questionnaire. Exploratory comparative statistics were used to detect differences between arms with χ2 and Kruskal-Wallis testing. RESULTS: Five institutions enrolled 23 patients. However, accrual was less than expected. Eleven and 12 patients were in the placebo and lisinopril arms, respectively (mean age, 63.5 years; male, 62%). Baseline characteristics were balanced. Eighteen patients (86%) were former or current smokers. The primary endpoint was met; neither arm had grade 3 or higher hypotension, acute kidney injury, allergic reaction (medication-induced cough), or anaphylaxis (medication-related angioedema). Few PRO measures suggested that compared with the placebo arm, patients receiving lisinopril had less cough, less shortness of breath, fewer symptoms from lung cancer, less dyspnea with both walking and climbing stairs, and better overall quality of life (for all, P < .05). CONCLUSIONS: Although underpowered because of low accrual, our results suggest that there was a clinical signal for safety-and possibly beneficial by limited PRO measures-in concurrently administering lisinopril during thoracic CRT to mitigate or prevent RT-induced pulmonary distress. Our results showed that a definitive, larger-scale, randomized phase 3 trial is needed in the future.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Sio TT, Atherton PJ, Pederson LD, et al. Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial. Int J Radiat Oncol Biol Phys. 2018. PMID: 30395904. doi:10.1016/j.ijrobp.2018.10.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。